Ezetimibe vs Inclisiran in Coronary Artery Disease and Hyperlipidemia: A Propensity-Matched Analysis. [PDF]
JACC AdvAkbar UA +7 more
europepmc +1 more source
Longitudinal management and novel pharmacological interactions in a patient with HeFH, 21-OHD, and kawasaki disease: a 6-year clinical follow-up. [PDF]
Front Endocrinol (Lausanne)Zhang Y, Yuan X, Yang X, Chen R.
europepmc +1 more source
Utilizing Electronic Health Record-Based Alerts to Increase Prescription of Lipid-Lowering Therapies in Patients Admitted With Acute Coronary Syndromes. [PDF]
JACC Case RepRowland S +4 more
europepmc +1 more source
Impact of Age on Lipid-Lowering Therapy Prescriptions and LDL-Cholesterol Control: Insights from the PORTRAIT-DYS Study. [PDF]
Glob HeartGavina C +8 more
europepmc +1 more source
Subcutaneous nodules on the elbows of a teenager. [PDF]
JAAD Case RepHaveric A +5 more
europepmc +1 more source
Physician Disagreement With Guidelines as a Critical Barrier to Achieving LDL-C Targets in Very High-Risk Patients: An Implementation Science Study. [PDF]
J Korean Med SciCho KH +15 more
europepmc +1 more source
Effects of inclisiran therapy on metabolomic and lipoproteomic profiles in dyslipidemic patients. [PDF]
Front PharmacolPatrussi J +11 more
europepmc +1 more source
Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care? [PDF]
Curr Cardiol RepBrandts J, Marx N.
europepmc +1 more source
Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants. [PDF]
Naunyn Schmiedebergs Arch PharmacolGoh S, Huh KY, Lee S, Cho JY, Yu KS.
europepmc +1 more source